Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 3
1(25.0%)
N/A
1(25.0%)
4Total
Phase 2(2)
Phase 3(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02509286Phase 3Active Not Recruiting

Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus

Role: collaborator

NCT03885102Not ApplicableCompleted

Dialysis Training Therapy: The DiaTT Trial

Role: collaborator

NCT02396628Phase 2Terminated

Ruxolitinib In GvHD

Role: collaborator

NCT02569125Phase 2Withdrawn

Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome

Role: collaborator

All 4 trials loaded